GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Little Green Pharma Ltd (ASX:LGP) » Definitions » ROE %

Little Green Pharma (ASX:LGP) ROE % : -5.35% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Little Green Pharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Little Green Pharma's annualized net income for the quarter that ended in Sep. 2023 was A$-4.36 Mil. Little Green Pharma's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was A$81.46 Mil. Therefore, Little Green Pharma's annualized ROE % for the quarter that ended in Sep. 2023 was -5.35%.

The historical rank and industry rank for Little Green Pharma's ROE % or its related term are showing as below:

ASX:LGP' s ROE % Range Over the Past 10 Years
Min: -70.65   Med: -10.45   Max: 46.34
Current: -2.68

During the past 4 years, Little Green Pharma's highest ROE % was 46.34%. The lowest was -70.65%. And the median was -10.45%.

ASX:LGP's ROE % is ranked worse than
64.9% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.385 vs ASX:LGP: -2.68

Little Green Pharma ROE % Historical Data

The historical data trend for Little Green Pharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Little Green Pharma ROE % Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23
ROE %
- -70.65 46.34 -10.45

Little Green Pharma Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Mar23 Sep23
ROE % Get a 7-Day Free Trial 7.10 88.64 -18.85 - -5.35

Competitive Comparison of Little Green Pharma's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Little Green Pharma's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's ROE % distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's ROE % falls into.



Little Green Pharma ROE % Calculation

Little Green Pharma's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Jun. 2021 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-9.205/( (93.889+82.228)/ 2 )
=-9.205/88.0585
=-10.45 %

Little Green Pharma's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-4.36/( (82.228+80.695)/ 2 )
=-4.36/81.4615
=-5.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Little Green Pharma  (ASX:LGP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-4.36/81.4615
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.36 / 25.302)*(25.302 / 95.7645)*(95.7645 / 81.4615)
=Net Margin %*Asset Turnover*Equity Multiplier
=-17.23 %*0.2642*1.1756
=ROA %*Equity Multiplier
=-4.55 %*1.1756
=-5.35 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-4.36/81.4615
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.36 / -4.16) * (-4.16 / -5.736) * (-5.736 / 25.302) * (25.302 / 95.7645) * (95.7645 / 81.4615)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0481 * 0.7252 * -22.67 % * 0.2642 * 1.1756
=-5.35 %

Note: The net income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Little Green Pharma ROE % Related Terms

Thank you for viewing the detailed overview of Little Green Pharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Little Green Pharma (ASX:LGP) Business Description

Traded in Other Exchanges
N/A
Address
66 Kings Park Road, Level 2, Suite 2, West Perth, Perth, WA, AUS, 6005
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). The company offers LGP-branded medicinal cannabis oil products in the Australian and European markets.

Little Green Pharma (ASX:LGP) Headlines

No Headlines